Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns – Cancer Therapy Advisor
Cancer Therapy Advisor |
Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns
Cancer Therapy Advisor … other minority (8.5%) patients, and 13.2% were of unknown race/ethnicity. Just 8.3% of patients were tested for PD-L1 expression levels prior to initiating anti–PD-1 therapy; mutational analysis of EGFR and ALK rearrangements was performed among 64 … |
